A Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-generation Maturation Inhibitor, in Participants With Human Immunodeficiency Virus Type 1 Infection.

MLA

DeJesus, Edwin, et al. “A Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-Generation Maturation Inhibitor, in Participants With Human Immunodeficiency Virus Type 1 Infection.” Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, vol. 71, no. 5, Aug. 2020, pp. 1255–62. EBSCOhost, https://doi.org/10.1093/cid/ciz938.

APA

DeJesus, E., Harward, S., Jewell, R. C., Johnson, M., Dumont, E., Wilches, V., Halliday, F., Talarico, C. L., Jeffrey, J., Gan, J., Xu, J., Felizarta, F., Scribner, A., Ramgopal, M., Benson, P., & Johns, B. A. (2020). A Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-generation Maturation Inhibitor, in Participants With Human Immunodeficiency Virus Type 1 Infection. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, 71(5), 1255–1262. https://doi.org/10.1093/cid/ciz938

Chicago

DeJesus, Edwin, Sara Harward, Roxanne C Jewell, Mark Johnson, Etienne Dumont, Viviana Wilches, Fiona Halliday, et al. 2020. “A Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-Generation Maturation Inhibitor, in Participants With Human Immunodeficiency Virus Type 1 Infection.” Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 71 (5): 1255–62. doi:10.1093/cid/ciz938.